<DOC>
	<DOCNO>NCT00315887</DOCNO>
	<brief_summary>The objective study assess safety efficacy buprenorphine transdermal system ( 5 , 10 , 20 mg ) comparison placebo transdermal system hydrocodone/acetaminophen subject chronic back pain . The double-blind treatment intervention duration 56 day time supplemental analgesic medication ( ibuprofen ) provide subject addition study drug .</brief_summary>
	<brief_title>The Safety Efficacy Buprenorphine Transdermal Delivery System Subjects With Chronic Back Pain .</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic twenty-five year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain . Transdermal system may offer advantage currently indicate oral product include ease convenience use , improve compliance , possible reduction patient care , prolong consistent delivery drug .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>clinical evidence chronic back pain related intervertebral disc disease , nerve root entrapment , spondylolithesis , osteoarthritis , , similar nonmalignant condition . back pain treat opioidcontaining analgesic dose equal less equivalent 90 mg oral morphine per day 12 few capsule tablet opioid combination analgesic per day . receive opioids average daily dose great 90 mg oral morphine equivalent patient receive 12 tablet per day shortacting opioidcontaining product . schedule surgery ( include dental ) study period involve use pre and/or postoperative analgesic anesthetic . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>low back pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
</DOC>